Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.49 |
| ▸ | WNT1 | P04628 | 9/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 6/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20054506 | 0.91 | GSK3B (0.45) | GSK3BDYRK1AWNT1ABL1PDPK1 | |
| SCHEMBL20054445 | 0.87 | GSK3B (0.48) | GSK3BDYRK1AWNT1HDAC3HDAC1 | |
| SCHEMBL20054567 | 0.87 | GSK3B (0.48) | GSK3BDYRK1AWNT1HDAC3HDAC1 | |
| SCHEMBL20054480 | 0.86 | GSK3B (0.61) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL20054523 | 0.85 | GSK3B (0.53) | GSK3BDYRK1AWNT1HDAC3HDAC1 | |
| SCHEMBL20221305 | 0.84 | GSK3B (0.44) | GSK3BDYRK1AWNT1HDAC3HDAC1 | |
| SCHEMBL20054419 | 0.83 | GSK3B (0.60) | GSK3BDYRK1AWNT1HDAC3HDAC1 | |
| SCHEMBL20054426 | 0.80 | GSK3B (0.37) | GSK3BDYRK1AWNT1PDPK1 | |
| SCHEMBL20054393 | 0.80 | GSK3B (0.43) | GSK3BDYRK1AWNT1HDAC3HDAC1 | |
| SCHEMBL20221280 | 0.78 | GSK3B (0.37) | GSK3BDYRK1AWNT1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |